Effect of high fiber intake in fish oil-treated patients with non-insulin-dependent diabetes mellitus.

The short-term effect of high fiber intake on fish-oil treatment in 15 free-living, non-insulin-dependent diabetic patients was evaluated by using a controlled, sequential study design. During an 8-wk fish-oil-treatment period when patients received 20 g fish oil/d, the usual daily fiber intake was increased with a 15-g pectin supplement at midpoint. Fish oil alone lowered triacylglycerol and very-low-density-lipoprotein-cholesterol concentrations by 41% and 36%, respectively (both P < 0.01 by the end of the treatment period) with unchanged mean total, low-density-, and high-density-lipoprotein-cholesterol concentrations. When the fiber intake was increased, however, total and low-density-lipoprotein-cholesterol concentrations decreased significantly (P < 0.001 and < 0.05, respectively) with fish-oil treatment. The cholesterol ester fraction of plasma lipids was reduced by 34% when compared with fish oil alone (P < 0.05). The plasma triacylglycerol fraction decreased further by 44% (P < 0.001). Other beneficial effects observed included a 30% decline in the fatty acid fraction (P < 0.002) by end of the treatment period. Diabetic control was maintained during the 12-wk study. In conclusion, a high fiber intake may be beneficial in fish oil-treated diabetic patients.

Effect of theophylline on urinary excretion of 3-methylhistidine in patients with lung disease.

Theophylline, which is commonly used for the treatment of lung disease, has been reported to stimulate lipolysis, glycogenolysis, and gluconeogenesis. This study was initiated to investigate whether theophylline therapy also induces catabolic changes in protein metabolism and thus provides additional substrates for energy metabolism. Urinary excretion of 3-methylhistidine (3-MH) as an index of myofibrillar protein catabolism was measured at the end of a 7-day treatment period with theophylline and a 5-day basal untreated control period in eight patients with stable chronic obstructive pulmonary disease (COPD), eight patients with stable asthma, and eight normal healthy volunteers. Basal urinary 3-MH excretion and 3-MH/creatinine ratios, and nutritional indices assessed were not different in the three groups. Under similar drug (except theophylline), dietary, and activity regimens, comparison of the two experimental periods showed that theophylline increased mean urinary 3-MH excretion and 3-MH/creatinine ratios in all three groups of subjects. These changes were significant in the COPD and asthmatic patients (mean 3-MH +/- SD, mumol/d: basal, 176 +/- 46 v 206 +/- 46; and basal, 190 +/- 27 v 216 +/- 45, respectively, P less than .05) and persisted when 3-MH values were normalized to creatinine excretion (15% to 38%, P less than .005). In contrast, the mean increment was marginal in the group of normal volunteers and this discrepancy of effect between groups may be attributed to dietary noncompliance. Furthermore, the response of the COPD group was significantly greater than the asthmatic and control groups (1.8x and 11.3x, respectively, P less than .05). In conclusion, these results suggest that theophylline may enhance myofibrillar protein degradation.(ABSTRACT TRUNCATED AT 250 WORDS)